ClinicalTrials.gg
CompletedNCT01081912Updated Dec 8, 2022Results posted

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

A Phase 3 interventional study of Placebo and Hydrocodone bitartrate in Back Pain Lower Back Chronic, sponsored by Zogenix, Inc.. Completed at 51 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-08.

Sponsored by Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.

Enrollment
57th of 1,092
510 · median 60
Started
2010
with 25 others
Phase 3
65 of 1,283
3 open now
Registered
110th of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 57th largest by enrollment of the 1,092 interventional ones that give a count, is one of 26 that started in 2010, is one of 65 in phase 3, and was the 110th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

252 more — sign in →

All 257 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and efficacy of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain.

Read the detailed description

A randomized Phase 3, placebo-controlled multi-center study to evaluate the safety, efficacy and tolerability of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain. Subjects will go through an open-label conversion and titration phase followed by a randomized double-blind treatment phase of Hydrocodone (HC)-Controlled-Release (CR) vs. Placebo. The trial will consist of a Screening Phase (up to 14 days), an open-label Conversion and Titration Phase (up to 6 weeks), a 12-week placebo-controlled Treatment Phase, and a 2-week Follow-Up Phone Call

03

Conditions studied

  • Back Pain Lower Back Chronic

Keywords

  • chronic pain
  • back pain
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have a clinical diagnosis of moderate to severe chronic lower back pain (CLBP)
  • Subjects must be classified as non-neuropathic, neuropathic, or symptomatic for more than 6 months after lower back pain (LBP) surgery
  • Subjects must in the Investigator's opinion qualify for around-the-clock opioid therapy for treatment of their chronic lower back pain (CLBP).
  • Subjects must have been taking opioids for at least 5 days/week for the past 4weeks
  • Subjects must have an average Clinic Pain Score of ≥ 4 on the 11-point (0-10) numeric rating scale (NRS) as an average for the last 24 hours of Screening
  • Subjects, in the opinion of the Investigator, must be considered to be in generally good health other then CLBP at Screening
  • Female subjects of must have a negative urine pregnancy test at the Screening Visit, and must consent to use a medically-acceptable method of throughout the entire study period.
  • Subjects must voluntarily provide written .

Exclusion criteria

Exclusion Criteria:

  • Any condition that would, in the opinion of the Investigator, preclude study participation or interfere with the assessment of pain and other symptoms of CLBP or increase the risk of opioid-related adverse events
  • A medical condition that, in the opinion of the Investigator, would compromise the subject's ability to swallow, absorb, metabolize, or excrete the study drug
  • A surgical procedure for back pain within 6 months
  • A nerve or plexus block, including epidural injections or facet blocks
  • A history of chemotherapy or confirmed within past 2 years
  • Any other chronic pain condition other than CLBP that, in the Investigator's opinion, would interfere with the assessment of LBP e.g. fibromyalgia, osteoarthritis, rheumatoid arthritis, migraine headaches requiring opioid treatment
  • Uncontrolled blood pressure, i.e., subject has a sitting systolic blood pressure >180 mmHg or \<90 mmHg, and/or a sitting diastolic blood pressure >120 mmHg or \<50 mmHg at Screening
  • A (BMI) >45 kg/m2
  • A Hospital Anxiety and Depression Scale (HADS) Index score of >12 in either depression or anxiety subscales or an established history of major depressive disorder that is poorly controlled with medication
  • A clinically significant abnormality in clinical chemistry, hematology or urinalysis
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
510 participants (actual)

Study arms

  • Active comparator
    Hydrocodone Bitartrate Capsules

    Hydrocodone Bitartrate Controlled-Release Capsules

    Drug: Hydrocodone bitartrate

  • Placebo comparator
    Placebo comparator

    Drug: Placebo

Interventions

  • DrugPlacebo

    Capsules, no active substance, shells identical to active comparator capsules

    Also known as: Sugar pill

  • DrugHydrocodoneStudies of HydrocodoneHydrocodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    dosage form: capsule Strengths 10mg, 20mg, 30mg, 40mg, 50mg

06

What researchers measure

Primary outcomes

  1. Mean Change in 24-hour Pain Intensity Ratings Scale (NRS).

    Change in average pain intensity as measured daily by Numeric Rating Scale (NRS) for Pain (0-10; where 0 = no pain, 10 = worst pain imaginable) comparing HC-ER with Placebo. Lower number equals better outcome.

    Time frame: Baseline to Day 85 (Treatment Phase)

Secondary outcomes

  1. Mean Change of the Clinic NRS Pain Intensity

    The change in pain intensity as measured in the clinic by a 0-10 Numeric Rating Scale (NRS)

    Time frame: Baseline to Day 85 visit

07

Results

Posted Apr 21, 2014

Participant flow

Conversion/Titration
Participant flow — Conversion/Titration
MilestoneConversion/Titration Phase - Open-LabelDouble-Blind Treatment PhaseDouble-Blind Treatment Phase: Placebo Comparator
Started51000
Completed30200
Not completed20800
Withdrew: Adverse event4700
Withdrew: Lack of efficacy1700
Withdrew: Lost to follow-up500
Withdrew: Physician decision200
Withdrew: Protocol violation6700
Withdrew: Withdrawal by subject2300
Withdrew: Non-compliance4700
Maintenance Treatment
Participant flow — Maintenance Treatment
MilestoneConversion/Titration Phase - Open-LabelDouble-Blind Treatment PhaseDouble-Blind Treatment Phase: Placebo Comparator
Started0151151
Completed012459
Not completed02792
Withdrew: Adverse event0212
Withdrew: Lack of efficacy01464
Withdrew: Lost to follow-up010
Withdrew: Physician decision001
Withdrew: Protocol violation012
Withdrew: Withdrawal by subject055
Withdrew: Non-compliance047
Withdrew: Withdrawal by medical monitor001

Outcome measures

PrimaryMean Change in 24-hour Pain Intensity Ratings Scale (NRS).

Change in average pain intensity as measured daily by Numeric Rating Scale (NRS) for Pain (0-10; where 0 = no pain, 10 = worst pain imaginable) comparing HC-ER with Placebo. Lower number equals better outcome.

Time frame:
Baseline to Day 85 (Treatment Phase)
Reported as:
Mean · units on a scale
Mean Change in 24-hour Pain Intensity Ratings Scale (NRS).
units on a scaleHydrocodone Bitartrate CapsulesPlacebo Comparator
Mean Change in 24-hour Pain Intensity Ratings Scale (NRS).0.48 ± 1.5630.96 ± 1.550
SecondaryMean Change of the Clinic NRS Pain Intensity

The change in pain intensity as measured in the clinic by a 0-10 Numeric Rating Scale (NRS)

Time frame:
Baseline to Day 85 visit

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events (AEs) were recorded up to 19 weeks, beginning at the Conversion and Titration Phase through 14 days after the last treatment administration (Treatment Phase).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-Label Conversion/Titration Phase—6/510 (1.2%)253/510 (49.6%)
Double Blind Treatment Phase: Hydrocodone Bitartrate Capsules—10/151 (6.6%)60/151 (39.7%)
Double Blind Treatment Phase: Placebo Comparator—0/151 (0%)46/151 (30.5%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventOpen-Label Conversion/Titration PhaseDouble Blind Treatment Phase: Hydrocodone Bitartrate CapsulesDouble Blind Treatment Phase: Placebo Comparator
Non-cardiac chest painGeneral disorders1/5101/1510/151
AnaemiaBlood and lymphatic system disorders0/5101/1510/151
Abdominal distensionGastrointestinal disorders0/5101/1510/151
DiarrhoeaGastrointestinal disorders0/5101/1510/151
NauseaGastrointestinal disorders0/5101/1510/151
Ovarian abscessInfections and infestations0/5101/1510/151
HypokalemiaMetabolism and nutrition disorders0/5101/1510/151
Intervertebral disc disorderMusculoskeletal and connective tissue disorders0/5101/1510/151
DepressionPsychiatric disorders0/5101/1510/151
Homicidal ideationPsychiatric disorders0/5101/1510/151
Most frequent other events
Showing 10 of 16
Most frequent other events
EventOpen-Label Conversion/Titration PhaseDouble Blind Treatment Phase: Hydrocodone Bitartrate CapsulesDouble Blind Treatment Phase: Placebo Comparator
ConstipationGastrointestinal disorders56/51012/1510/151
NauseaGastrointestinal disorders50/51011/1515/151
Withdrawal syndromePsychiatric disorders3/5101/1519/151
Urinary Tract InfectionInfections and infestations4/5108/1513/151
DiarrhoeaGastrointestinal disorders11/5104/1518/151
SomnolenceNervous system disorders24/5101/1510/151
VomitingGastrointestinal disorders14/5107/1511/151
InsomniaPsychiatric disorders12/5103/1517/151
FatigueGeneral disorders21/5101/1512/151
Back PainMusculoskeletal and connective tissue disorders4/5106/1515/151

Baseline characteristics

Out of 510 subjects treated with Hydrocodone Bitartrate Extended Release (HC-ER) capsules in the Conversion/Titration Phase, 208 subjects discontinued early and 151 subjects were randomized into each of the two treatment groups (Maintenance HC-ER Treatment and Placebo Treatment).

Age, Categorical
Age, Categorical(Participants)Open-label Conversion/Titration Phase
<=18 years0
Between 18 and 65 years462
>=65 years48
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Conversion/Titration Phase
Female273
Male237
Region of Enrollment
Region of Enrollment(participants)Open-label Conversion/Titration Phase
United States510
08

Study locations

51 sites
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Clopton Clinic
    Jonesboro, Arkansas 72401, United States
  • Advanced Clinical Research Institute
    Anaheim, California 92801, United States
  • Neuro-Pain Medical Center, Inc.
    Fresno, California 93710, United States
  • Pacific Coast Pain Management Center
    Laguna Hills, California 92637, United States
  • Clinicos, LLC
    Colorado Springs, Colorado 80904, United States
  • Interwest Rehabilitation, LLC
    Littleton, Colorado 80122, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Florida Institute of Medical Research
    Jacksonville, Florida 32257, United States
  • Peninsula Research, Inc.
    Ormond Beach, Florida 32174, United States
  • Gold Coast Research
    Plantation, Florida 33317, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • Perimeter Institute for Clinical Research, Inc.
    Atlanta, Georgia 30338, United States
  • River Birch Research Alliance, LLC
    Blue Ridge, Georgia 30513, United States
  • Georgia Institute for Clinical Research, LLC
    Marietta, Georgia 30060, United States
  • Georgia Clinical Research
    Snellville, Georgia 30078, United States
  • Suburban Clinical Research
    Chicago, Illinois 60490, United States
  • Destiny Clinical Research, LLC
    Evansville, Indiana 47714, United States
  • Integrated Clinical Trials Services, Inc.
    West Des Moines, Iowa 50265, United States
  • International Clinical Research Institute
    Leawood, Kansas 66211, United States
  • Clinical Trials Technology, Inc
    Prairie Village, Kansas 66206, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Clinical Trials Management
    Metairie, Louisiana 70006, United States
  • Best Clinical Trials, LLC
    New Orleans, Louisiana 70115, United States
  • River Cities Clinical Research Center
    Shreveport, Louisiana 71105, United States
  • NECCR Internal Medicine & Cardiology Associates, LLC
    Fall River, Massachusetts 02720, United States
  • Center for Clinical Trials
    Biloxi, Mississippi 39531, United States
  • Research West, LLC
    Kalispell, Montana 59901, United States
  • Office of Danka Michaels, MD
    Las Vegas, Nevada 89128, United States
  • South Jersey Medical Associates
    Blackwood, New Jersey 08012, United States
  • CRI Worldwide, LLC
    Willingboro, New Jersey 08046, United States
  • Five Towns Neuroscience Research
    Cedarhurst, New York 11516, United States
  • Upstate Clinical Research Associates
    Williamsville, New York 14221, United States
  • Center for Clinical Research LLC
    Winston-Salem, North Carolina 27103, United States
  • IVA Research
    Cincinnati, Ohio 45245, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Neuropsychiatric Research Center
    Oklahoma City, Oklahoma 73109, United States
  • Brandywine Clinical Research
    Downingtown, Pennsylvania 19335, United States
  • Feasterville Family Health Care Center
    Feasterville, Pennsylvania 19053, United States
  • New England Center for Clinical Research
    Cranston, Rhode Island 02920, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Integrity Clinical Research, LLC
    Milan, Tennessee 38358, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Innovative Clinical Trials
    San Antonio, Texas 78229, United States
  • Invisions Consultants, LLC
    San Antonio, Texas 78229, United States
  • Clinical Trial Network
    Spring, Texas 77386, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • Hypothe Test, LLC
    Roanoke, Virginia 24018, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 2 years 6 months after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2010
First posted
Mar 5, 2010
Start
Mar 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results delay requested
Jul 18, 2012
Results first posted
Apr 21, 2014
Last update
Dec 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01081912
Lead sponsor
Zogenix, Inc.
Responsible party
Sponsor
First posted
Mar 5, 2010
Start date
Mar 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Apr 21, 2014
Last update
Dec 8, 2022

Study contacts

Kevin Romanko, DPM
study director · Zogenix, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydrocodone

Start the discussion